Article title: Specialized multidisciplinary care improves ALS survival in Belgium: a population-based retrospective study
Authors: Frederik Hobin, Joke De Vocht, Nikita Lamaire, Hilde Beyens, Fouke Ombelet & Philip Van Damme
Journal: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Bibliometrics: Volume 25, Number 3–4, pages 282–289
DOI: https://doi.org/10.1080/21678421.2024.2304058
The article mentioned above contained an error when it was first published online. The months “36” in the following sentence “The only EMA-approved drug for ALS so far is the sodium-channel inhibitor Riluzole, which counters neuronal glutamatergic excitotoxicity, prolonging survival by 36 months on average (6–8).” of the “Introduction” section was incorrect.
The article has been republished online after correcting the months from “36” to “3–6” and the sentence now reads as “The only EMA-approved drug for ALS so far is the sodium-channel inhibitor Riluzole, which counters neuronal glutamatergic excitotoxicity, prolonging survival by 3–6 months on average (6–8).”